Vol 7, No 4 (2022)
Review article
Published online: 2022-11-29

open access

Page views 3597
Article views/downloads 363
Get Citation

Connect on Social Media

Connect on Social Media

Depressive and anxiety disorders in the cardiological conditions: psychological interventions

Remigiusz Szczepanowski12, Monika Wójta-Kempa3, Agnieszka Pawlak4, Jolanta Kolasa45, Izabella Uchmanowicz67, Michal Czapla789, Tomasz Cyrkot1011
Medical Research Journal 2022;7(4):333-339.

Abstract

Cardiovascular disease (CVD) remains a leading cause of mortality worldwide, despite diagnostic and pharmacological advances. These adverse effects lead to the search for new etiological factors and effective ways to prevent, treat and rehabilitate CVD. The impact of psychological factors on the development of CVD has gained scientific recognition. Mental and mood disorders, such as depressive disorders, anxiety disorders, and post-traumatic stress disorder (PTSD), can contribute to CVD and significantly affect the quality of life and prognosis of a CVD patient, often contributing to premature death. Therefore, it is essential to study the socio-demographic and psychosocial factors that are most likely to support pro-health behaviour and identify effective psychotherapeutic interventions for CVD patients. These findings result in new interventions, such as meta-cognitive therapy and mindfulness-based training, which promote healthy behaviours and improve clinical conditions and prognosis in CVD patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Cardiovascular Diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (4 December 2021).
  2. Bateman RM, Sharpe MD, Jagger JE, et al. 36th International Symposium on Intensive Care and Emergency Medicine. Crit Care. 2016; 94(Suppl 2).
  3. Chauvet-Gelinier JC, Bonin B. Stress, anxiety and depression in heart disease patients: A major challenge for cardiac rehabilitation. Ann Phys Rehabil Med. 2017; 60(1): 6–12.
  4. Conner M. Cognitive determinants of health behavior. In: Steptoe A. ed. Handbook of Behavioral Medicine. Springer Verlag, New York 2010.
  5. Shockey TM, Sussell AL, Odom EC. Cardiovascular health status by occupational group - 21 States, 2013. MMWR Morb Mortal Wkly Rep. 2016; 65(31): 793–798.
  6. Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018; 25(3): 247–259.
  7. Rozanski A, Kubzansky LD. Psychologic functioning and physical health: a paradigm of flexibility. Psychosom Med. 2005; 67 Suppl 1: S47–S53.
  8. Harshfield EL, Pennells L, Schwartz JE, et al. Emerging Risk Factors Collaboration. Association between depressive symptoms and incident cardiovascular diseases. JAMA. 2020; 324(23): 2396–2405.
  9. Batelaan NM, Seldenrijk A, Bot M, et al. Anxiety and new onset of cardiovascular disease: critical review and meta-analysis. Br J Psychiatry. 2016; 208(3): 223–231.
  10. Rao A, Zecchin R, Newton PJ, et al. The prevalence and impact of depression and anxiety in cardiac rehabilitation: A longitudinal cohort study. Eur J Prev Cardiol. 2020; 27(5): 478–489.
  11. Murphy B, Le Grande M, Alvarenga M, et al. Anxiety and depression after a cardiac event: prevalence and predictors. Front Psychol. 2019; 10: 3010.
  12. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med. 2002; 23(1): 51–61.
  13. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med. 2003; 65(2): 201–210.
  14. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373(9667): 929–940.
  15. Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med. 2010; 72(6): 563–569.
  16. Martens EJ, de Jonge P, Na B, et al. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease:The Heart and Soul Study. Arch Gen Psychiatry. 2010; 67(7): 750–758.
  17. Roest AM, Zuidersma M, de Jonge P. Myocardial infarction and generalised anxiety disorder: 10-year follow-up. Br J Psychiatry. 2012; 200(4): 324–329.
  18. Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry. 2007; 64(10): 1153–1160.
  19. Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J. 2013; 166(5): 806–814.
  20. Kutz I, Garb R, David D. Post-traumatic stress disorder following myocardial infarction. Gen Hosp Psychiatry. 1988; 10(3): 169–176.
  21. Davidson KW, Kupfer DJ, Bigger JT, et al. National Heart, Lung, and Blood Institute Working Group. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. Ann Behav Med. 2006; 32(2): 121–126.
  22. Wells A, McNicol K, Reeves D, et al. Metacognitive therapy home-based self-help for cardiac rehabilitation patients experiencing anxiety and depressive symptoms: study protocol for a feasibility randomised controlled trial (PATHWAY Home-MCT). Trials. 2018; 19(1): 444.
  23. Davidson KW, Kupfer DJ, Bigger JT, et al. National Heart, Lung, and Blood Institute Working Group. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. Ann Behav Med. 2006; 32(2): 121–126.
  24. Krishnan KR, Delong M, Kraemer H, et al. Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry. 2002; 52(6): 559–588.
  25. Machado S, Sancassiani F, Paes F, et al. Panic disorder and cardiovascular diseases: an overview. Int Rev Psychiatry. 2017; 29(5): 436–444.
  26. Bravo-Escobar R, González-Represas A, Gómez-González AM, et al. Effectiveness and safety of a home-based cardiac rehabilitation programme of mixed surveillance in patients with ischemic heart disease at moderate cardiovascular risk: A randomised, controlled clinical trial. BMC Cardiovasc Disord. 2017; 17(1): 66.
  27. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160(14): 2101–2107.
  28. Smith RW, Barnes I, Green J, et al. Social isolation and risk of heart disease and stroke: analysis of two large UK prospective studies. Lancet Public Health. 2021; 6(4): e232–e239.
  29. Holt-Lunstad J, Smith TB. Loneliness and social isolation as risk factors for CVD: implications for evidence-based patient care and scientific inquiry. Heart. 2016; 102(13): 987–989.
  30. Gorini A, Giuliani M, Raggio L, et al. Depressive and anxiety symptoms screening in cardiac inpatients: a virtuous Italian approach to psychocardiology. Int J Environ Res Public Health. 2020; 17(14).
  31. Haefner DP, Kirscht JP. Motivational and behavioral effects of modifying health beliefs. Public Health Rep (1896). 1970; 85(6): 478–484.
  32. Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med. 2013; 75(4): 335–349.
  33. Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol. 2014; 21(6): 664–681.
  34. Metacognitive Therapy for Anxiety and Depression, Guilford Press. https://www.guilford.com/books/Metacognitive-Therapy-for-Anxiety-and-Depression/Adrian-Wells/978160918496 (4 December 2021).
  35. Wells A, Reeves D, Heal C, et al. Establishing the feasibility of group metacognitive therapy for anxiety and depression in cardiac rehabilitation: A single-blind randomized pilot study. Front Psychiatry. 2020; 11: 582.
  36. Hayes SC, Hofmann SG. The third wave of cognitive behavioral therapy and the rise of process-based care. World Psychiatry. 2017; 16(3): 245–246.
  37. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982; 4(1): 33–47.
  38. Morgan D. Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. Psychother Res. 2003; 13(1): 123–125.
  39. Zou H, Cao Xi, Geng J, et al. Effects of mindfulness-based interventions on health-related outcomes for patients with heart failure: a systematic review. Eur J Cardiovasc Nurs. 2020; 19(1): 44–54.
  40. Abbott RA, Whear R, Rodgers LR, et al. Effectiveness of mindfulness-based stress reduction and mindfulness based cognitive therapy in vascular disease: A systematic review and meta-analysis of randomised controlled trials. J Psychosom Res. 2014; 76(5): 341–351.
  41. Conversano C, Orrù G, Pozza A, et al. Is mindfulness-based stress reduction effective for people with hypertension? A systematic review and meta-analysis of 30 years of evidence. Int J Environ Res Public Health. 2021; 18(6).
  42. Scott-Sheldon LAJ, Gathright EC, Donahue ML, et al. Mindfulness-based interventions for adults with cardiovascular disease: a systematic review and meta-analysis. Ann Behav Med. 2020; 54(1): 67–73.
  43. Heo S, McSweeney J, Ounpraseuth S, et al. Testing a holistic meditation intervention to address psychosocial distress in patients with heart failure: A pilot study. J Cardiovasc Nurs. 2018; 33(2): 126–134.
  44. Loucks EB, Schuman-Olivier Z, Britton WB, et al. Mindfulness and cardiovascular disease risk: state of the evidence, plausible mechanisms, and theoretical framework. Curr Cardiol Rep. 2015; 17(12): 112.
  45. Abbott RA, Whear R, Rodgers LR, et al. Effectiveness of mindfulness-based stress reduction and mindfulness based cognitive therapy in vascular disease: A systematic review and meta-analysis of randomised controlled trials. J Psychosom Res. 2014; 76(5): 341–351.
  46. Scott-Sheldon LAJ, Gathright EC, Donahue ML, et al. Mindfulness-based interventions for adults with cardiovascular disease: a systematic review and meta-analysis. Ann Behav Med. 2020; 54(1): 67–73.
  47. Schuman-Olivier Z, Trombka M, Lovas DA, et al. Mindfulness and behavior change. Harv Rev Psychiatry. 2020; 28(6): 371–394.
  48. de Souza IC, de Barros VV, Gomide HP, et al. Mindfulness-based interventions for the treatment of smoking: a systematic literature review. J Altern Complement Med. 2015; 21(3): 129–140.
  49. Levine GN, Lange RA, Bairey-Merz CN, et al. American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension. Meditation and cardiovascular risk reduction: a scientific statement from the American Heart Association. J Am Heart Assoc. 2017; 6(10).
  50. Krittanawong C, Kumar A, Wang Z, et al. Pet ownership and cardiovascular health in the US general population. Am J Cardiol. 2020; 125(8): 1158–1161.